Literature DB >> 19050684

Molecular mechanisms of metastasis in prostate cancer.

Noel W Clarke1, Claire A Hart, Mick D Brown.   

Abstract

Prostate cancer (PCa) preferentially metastasizes to the bone marrow stroma of the axial skeleton. This activity is the principal cause of PCa morbidity and mortality. The exact mechanism of PCa metastasis is currently unknown, although considerable progress has been made in determining the key players in this process. In this review, we present the current understanding of the molecular processes driving PCa metastasis to the bone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050684      PMCID: PMC3735202          DOI: 10.1038/aja.2008.29

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  88 in total

1.  New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade.

Authors:  J B Nelson; S H Nguyen; J R Wu-Wong; T J Opgenorth; D B Dixon; L W Chung; N Inoue
Journal:  Urology       Date:  1999-05       Impact factor: 2.649

2.  Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis.

Authors:  Z Zheng; J Pan; B Chu; Y C Wong; A L Cheung; S W Tsao
Journal:  Hum Pathol       Date:  1999-04       Impact factor: 3.466

Review 3.  The normal structure and function of CD44 and its role in neoplasia.

Authors:  R J Sneath; D C Mangham
Journal:  Mol Pathol       Date:  1998-08

4.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

Authors:  A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

5.  Breast cancer cells interact with osteoblasts to support osteoclast formation.

Authors:  R J Thomas; T A Guise; J J Yin; J Elliott; N J Horwood; T J Martin; M T Gillespie
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

Review 6.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

Authors:  T Suda; N Takahashi; N Udagawa; E Jimi; M T Gillespie; T J Martin
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

Review 7.  Osteoblasts in prostate cancer metastasis to bone.

Authors:  Christopher J Logothetis; Sue-Hwa Lin
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

Review 8.  Cell-cell interactions during transendothelial migration of tumor cells.

Authors:  E B Voura; M Sandig; C H Siu
Journal:  Microsc Res Tech       Date:  1998-11-01       Impact factor: 2.769

9.  Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors.

Authors:  A Aiuti; M Tavian; A Cipponi; F Ficara; E Zappone; J Hoxie; B Peault; C Bordignon
Journal:  Eur J Immunol       Date:  1999-06       Impact factor: 5.532

10.  E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion.

Authors:  N Morita; H Uemura; K Tsumatani; M Cho; Y Hirao; E Okajima; N Konishi; Y Hiasa
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  35 in total

Review 1.  Recent advances in bone-targeted therapies of metastatic prostate cancer.

Authors:  Xiyun Deng; Guangchun He; Junwen Liu; Feijun Luo; Xiaoning Peng; Shigang Tang; Zhiyong Gao; Qinlu Lin; Jill M Keller; Tao Yang; Evan T Keller
Journal:  Cancer Treat Rev       Date:  2014-04-16       Impact factor: 12.111

2.  Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro.

Authors:  J C Evans; J McCarthy; C Torres-Fuentes; J F Cryan; J Ogier; R Darcy; R W Watson; C M O'Driscoll
Journal:  Gene Ther       Date:  2015-05-25       Impact factor: 5.250

3.  Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.

Authors:  Benjamin M Johnson; Bently P Doonan; Faisal F Radwan; Azizul Haque
Journal:  Open Prost Cancer J       Date:  2010-01-01

4.  Cancer-bone microenvironmental interactions promotes STAT3 signaling.

Authors:  Veronica M Henderson; Ohuod Hawsawi; Liza J Burton; Taaliah Campbell; Kennedi Trice; Jodi Dougan; Simone M Howard; Valerie A Odero-Marah
Journal:  Mol Carcinog       Date:  2019-05-02       Impact factor: 4.784

Review 5.  Steps in prostate cancer progression that lead to bone metastasis.

Authors:  Jung-Kang Jin; Farshid Dayyani; Gary E Gallick
Journal:  Int J Cancer       Date:  2011-03-28       Impact factor: 7.396

Review 6.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

Review 7.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

8.  An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.

Authors:  Hai-Liang Zhang; Xiao-Jian Qin; Da-Long Cao; Yao Zhu; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2013-02-04       Impact factor: 3.285

9.  Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.

Authors:  Siddhartha Yadav; Steven N Hart; Chunling Hu; David Hillman; Kun Y Lee; Rohan Gnanaolivu; Jie Na; Eric C Polley; Fergus J Couch; Manish Kohli
Journal:  JCO Precis Oncol       Date:  2019-09-17

Review 10.  Molecular tracing of prostate cancer lethality.

Authors:  Yuanshuo Alice Wang; John Sfakianos; Ashutosh K Tewari; Carlos Cordon-Cardo; Natasha Kyprianou
Journal:  Oncogene       Date:  2020-10-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.